BRAF and melanoma: Trametinib showed favorable clinical efficacy in a phase III trial in treatment of BRAF-mutated melanoma patients in comparison to chemotherapy [median progression-free survival (PFS) was 4.8 vs 1.5 months (p < 0.001); 6 months OS was 81 vs 67 % (p < 0.01)] [4].